Jove
Visualize
お問い合わせ

関連する概念動画

Drug Discovery: Overview01:26

Drug Discovery: Overview

12.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.1K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

829
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
829
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

24
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
24
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

272
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
272
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

280
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
280

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2021
Same author

Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse Model".

Journal of medicinal chemistry·2021
Same author

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse Model.

Journal of medicinal chemistry·2020
Same author

Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment.

ACS omega·2020
Same author

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Antimicrobial agents and chemotherapy·2018
Same author

Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.

Journal of medicinal chemistry·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Feb 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

リソースが限られた環境での薬物発見の最適化: マルチパラメータ最適化とデータ主導のワークフロー

Aloysius T Nchinda1, Karsten Menzel2

  • 1Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.

ACS medicinal chemistry letters
|February 18, 2026
PubMed
まとめ
この要約は機械生成です。

薬剤の発見は資源密集的である. この研究は,資源が限られた組織が,研究上のギャップを特定し,無料のツールとデータ主導の意思決定を使用して化学エンティティを戦略的に前進させるためのワークフローを提供します.

キーワード:
ドラッグ・ディスカバリー・ドラッグ・ディスカバリーECCS ECCSは,ECCSという名前で作られています.MPOのMPOは,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOが,MPOは,MPOが,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは,MPOは資源の制限 資源の制限

さらに関連する動画

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

697
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K

関連する実験動画

Last Updated: Feb 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

697
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K

科学分野:

  • 薬剤の発見と開発について
  • 薬剤化学 薬剤化学について
  • 薬理学 薬理学とは

背景:

  • 新しい化学実体発見は,費用がかかり,時間がかかります.
  • 資源の制限により,薬剤開発における資産の効率的な配分が必要になります.
  • 研究のギャップを特定することは,医薬品開発パイプラインを最適化するために不可欠です.

研究 の 目的:

  • 限られたリソースを持つ薬剤開発組織の研究ギャップを特定する.
  • 資源の制限のある薬物発見の設定のための実用的なワークフローを提案する.
  • 化学エンティティを前進させるための戦略的意思決定を強化する.

主な方法:

  • 自由に利用できるコンピューティングツールを活用した.
  • 化学物のクリアランスメカニズムの決定に焦点を当てた.
  • データに基づいた意思決定プロセスを採用した.

主要な成果:

  • 資源の限られた環境に関連する特定の研究ギャップを特定しました.
  • 化学エンティティの進歩を合理化するためのワークフローを開発しました.
  • 薬剤発見の効率を最大化するための方法を実証した.

結論:

  • 無料ツールを使用した実用的なワークフローは,資源の限られた環境で薬物発見を最適化できます.
  • クリアランスメカニズムに関するデータに基づいた決定は,戦略的進歩の鍵です.
  • このアプローチは,治療開発における効率と資源配置を高めます.